Epizyme, Inc. (EPZM)

[snagem83]

I'm honestly liking this chart, new here, just bounced of it's low. I think the bottom is in an we are moving up.
Ima watch this on Monday and make a play to get in. Anything new that I may have missed? Tia

[maytepper]

Wedbush Reiterates Buy On Epizyme Following 2Q14 Update And Positive Early-Stage EPZ-6438 Data http://www.smarteranalyst.com/2014/08/18/35551/

[stocktrademan]

$EPZM recent news/filings

bullish

## source: finance.yahoo.com

Wed, 13 Aug 2014 15:09:17 GMT ~ Epizyme Announces Second Quarter 2014 Financial Results and Provides Corporate Update

[at noodls] - Presented pre-clinical data showing EPZ-6438 synergy with NHL standards of care and targeted therapies at American Society of Hematology (ASH) Meeting on Lymphoma Biology on August 12, 2014 Presented early ...

read full: http://www.noodls.com/view/C2C686B743993A6CC9C549E88C12E463E5C386B2
*********************************************************

Wed, 13 Aug 2014 11:43:57 GMT ~ EPIZYME, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/140813/epzm8-k.html
*********************************************************

Wed, 13 Aug 2014 11:31:00 GMT ~ Epizyme Announces Second Quarter 2014 Financial Results and Provides Corporate Update

[Business Wire] - Epizyme, Inc. , a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announce

read full: http://finance.yahoo.com/news/epizyme-announces-second-quarter-2014-113100229.html
*********************************************************

Wed, 13 Aug 2014 11:07:04 GMT ~ Q2 2014 Epizyme, Inc. Earnings Release - Before Market Open


read full: http://biz.yahoo.com/research/earncal/20140813.html?t=epzm
*********************************************************

Tue, 12 Aug 2014 21:32:40 GMT ~ Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology

[at noodls] - --In three dose cohorts completed to date: maximum tolerated dose (MTD) not reached; pharmacokinetics (PK) were dose-proportional; pharmacodynamic (PD) evidence of target inhibition was observed; objective ...

read full: http://www.noodls.com/view/75A83E9A50C380BB6A8AB93AB762A75A8CCB8BDD
*********************************************************


$EPZM charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$EPZM company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/EPZM/company-info
Ticker: $EPZM
OTC Market Place: Not Available
CIK code: not found
Company name: Epizyme, Inc.
Incorporated In:

Business Description:


$EPZM share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$EPZM extra dd links

Company name: Epizyme, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=EPZM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=EPZM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=EPZM+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/news - http://finance.yahoo.com/q/h?s=EPZM+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/EPZM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=EPZM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/EPZM
DTCC (dtcc.com): http://search2.dtcc.com/?q=Epizyme%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Epizyme%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Epizyme%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/EPZM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=EPZM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=EPZM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=EPZM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=EPZM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=EPZM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=EPZM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=EPZM+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/EPZM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=EPZM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/EPZM.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=EPZM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/EPZM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/EPZM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/EPZM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=EPZM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=EPZM



$EPZM DD Notes ~ http://www.ddnotesmaker.com/EPZM

[maytepper]

$EPZM Cowen Maintains Buy On Epizyme Following 2Q14 Results And Corporate Update http://www.smarteranalyst.com/2014/08/13/cowen-maintains-buy-on-epizyme-following-2q14-results-and-corporate-update/

[02opida]

34

[02opida]

sounds good

[02opida]

33

[murocman]

Science looks pretty good here. Thinking we could move to the $35-40 range on good data on the 12th.

GLTA,

Murocman

[02opida]

33

[02opida]

31

[02opida]

28.60

[02opida]

http://www.epizyme.com/wp-content/uploads/2014/06/Epizyme-ASH-Lymphoma-Release-6.10.14.pdf

[02opida]

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics
11:22a ET July 15, 2014 (Benzinga) Print


In a note released Tuesday morning, H.C. Wainwright analyst Andrew Fein initiated a Buy on both Epizyme (NASDAQ: EPZM) and Transition Therapeutics (NASDAQ: TTHI) and set respective price targets of $40 and $10.

Epizyme
Amid the transition of big pharma from genetics to epigenetics, Fein likes Epizyme's platform pipeline, technology expertise and market position in the histone methyltransferase space.

Fein noted that the company has around $240 million in cash-on-hand, which he expects will fund Epizyme's operations through 2016.

"We believe that EPZM shares will perform well in next six months as preclinical and mechanistic updates first grab and then focus investor attention in anticipation of value-driving clinical data from EPZ-5676 and EPZ-6438," wrote Fein.

[02opida]

34

[collhayyn_]

Epzm crushing it!!

[02opida]

31

[02opida]

next two weeks EPZM will be on the move up

[02opida]

29

[02opida]

Epizyme to Give Oral Presentation on Pre-Clinical Models and Early Clinical Observations of EZH2 Inhibitor EPZ-6438 at ASH Me...

Date : 06/10/2014 @ 8:00AM

[02opida]

CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. EPZM +0.01% , a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 4:30 p.m. ET to report first quarter 2014 financial results and provide a corporate update.

To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 40579133. The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com .

[Inoviorulez]

A good article on SA for Epizyme! Enjoy the read! http://seekingalpha.com/instablog/1058124-long-term-bio/2727383-epizyme-tackling-genetically-defined-cancers-one-step-at-a-time

[highstakes]

Lol

[edge]

Low 20's hanging on tight for the time being........stops in below 20.

[ottoman]

Grabbed a few more shares at $19. ok, this POS can start bouncing ANY time now!!

[ottoman]

"Epizyme Major Shareholder Buys $7,999,920 in Stock (EPZM)"

http://www.wkrb13.com/markets/229356/epizyme-major-shareholder-buys-7999920-in-stock-epzm/

Epizyme (NASDAQ:EPZM) major shareholder M James Barrett purchased 406,500 shares of the company’s stock on the open market in a transaction that occurred on Friday, November 15th. The shares were purchased at an average cost of $19.68 per share, for a total transaction of $7,999,920.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Epizyme (NASDAQ:EPZM) opened at 19.00 on Monday. Epizyme has a one year low of $18.10 and a one year high of $45.72. The stock has a 50-day moving average of $36.20 and a 200-day moving average of $33.03. The company’s market cap is $539.8 million.

Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Epizyme in a research note to investors on Friday. They now have a $32.00 price target on the stock, down previously from $42.00. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $34.50.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

[ottoman]

I suppose since the Nasdaq got whacked end of day, that a positive close is good, but I want this to bounce and stay bounced. lol.

I want $22 sometime this week!! :)

[bra1loga]

Took a position at 20$....

[Tinkerer]

I'm averaged in at $21 and waiting for a bounce this week. It won't be long and the stock will be back above $25.00/share.

[ottoman]

EPZM: "Epizyme Shares Crater - Present Buying Opportunity"

I'm still holding shares from 18.85.


http://seekingalpha.com/article/1845832-epizyme-shares-crater-present-buying-opportunity

[ottoman]

Epizyme Stock Rating Reaffirmed by Citigroup Inc. (EPZM)

They currently have a $32.00 target price on the stock, down from their previous target price of $42.00. Citigroup Inc.’s target price points to a potential upside of 60.48% from the company’s current price.

http://www.wkrb13.com/markets/228509/epizyme-stock-rating-reaffirmed-by-citigroup-inc-epzm/

[Tinkerer]

Patience...it will bounce higher. They are shaking out all the shares they can. Load up here. Next week will be a North-bound week. They have already shaken out a lot of people. Selling has nearly stopped. It is about time to move up again.

[Juschilln]

Ruttt rohhhh!

[ottoman]

Not looking good here. BOUNCE you POS!!!

[Juschilln]

Yep! I got $19.37s, let's go!

[Tinkerer]

I think you're right on the bounce here. I got in at 18.9 today. Tomorrow should be profitable for bouncers.

GLTA

[Juschilln]

I'm thinking this may be a good opportunity to catch a bounce. I'll be watching pretty close tomorrow. At the first sign of green I'll try to catch 10-20%. We'll see.

Good luck!

[mlkrborn]

November 14, 2013
08:07 EDT EPZM Epizyme's EPZ-5676 DOT1L inhibitor for leukemia shows positive Phase 1 results
Epizyme announced initial findings from an ongoing Phase 1 study of EPZ-5676, an inhibitor of the DOT1L histone methyltransferase being developed for the treatment of acute leukemia with alterations in the MLL gene. In four completed dose cohorts, with a total of 16 patients dosed, EPZ-5676 has been well-tolerated. There have been no dose-limiting toxicities and only one adverse event-related treatment discontinuation. Some MLL-r patients experienced resolution of leukemia-related symptoms and manifestations, including fevers, cachexia, and leukemia cutis. The study is ongoing with a fifth dose cohort currently enrolling. Epizyme plans to start the Phase 1 MLL-r only expansion stage with an 80 mg/m2/day administration schedule without a drug holiday and with possible continued dose escalation.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2013
10:00 EDT EPZM Epizyme falls 26.2%
Epizyme is down 26.2%, or $8.30, to $23.41
09:07 EDT EPZM Epizyme hosted a conference call
Subscribe for More Information
08:07 EDT EPZM Epizyme's EPZ-5676 DOT1L inhibitor for leukemia shows positive Phase 1 res

[mlkrborn]

About Epizyme Inc (NasdaqGM:EPZM)
Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

[mlkrborn]

Updated. But fell $10 to $21.. strange.
Epizyme's EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study
Date : 11/14/2013 @ 8:00AM
Source : PR Newswire (US)
Stock : EPIZYME, INC. (EPZM)
Quote : 21.2 -10.51 (-33.14%) @ 2:51PM

Epizyme's EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study
Print
Alert
EPIZYME, INC. (NASDAQ:EPZM)
Intraday Stock Chart

Today : Thursday 14 November 2013
Click Here for more EPIZYME, INC. Charts.

CAMBRIDGE, Mass., Nov. 14, 2013 /PRNewswire/ --

Four dose cohorts (12, 24, 36 and 54 mg/m2/day) completed (16 patients, 8 with acute leukemia with MLL-r) with 21-day on/7-day off administration schedule
Observations to date include:
No dose-limiting toxicities; maximum tolerated dose (MTD) not reached
Treatment effects, consistent with genetically defined therapeutic mechanism of action, observed in 4 of 8 acute leukemia patients with MLL-rearrangement (MLL-r); no effects observed in non-MLL-r patients
Dose-proportional exposure
Dose- and time-dependent methyl mark inhibition
Plan to initiate Phase 1 MLL-r only expansion stage in December 2013 starting at an 80 mg/m2/day uninterrupted treatment schedule, continued dose escalation possible
Epizyme will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss these data; slides will be available on www.epizyme.com prior to call

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced initial findings from an ongoing Phase 1 study of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT) being developed for the treatment of acute leukemia with alterations in the MLL gene.

"EPZ-5676 is a first-in-class inhibitor of the DOT1L HMT, and we are very pleased with the findings to date in the dose escalation stage of the ongoing two-stage Phase 1 study," said Robert J. Gould, Ph.D., chief executive officer, Epizyme. "The safety, pharmacokinetic, pharmacodynamic, and treatment effects observed in this study are consistent with our pre-clinical data. Based on these results, we plan to initiate the MLL-r only Phase 1 expansion stage in December 2013 and pediatric MLL-r and MLL-PTD studies in early 2014."

The dose escalation stage of the Phase 1 study, evaluating a 21-day on/7-day off administration schedule, is open to patients with heavily pre-treated advanced hematological malignancies, including but not limited to patients with acute leukemia with MLL-rearrangements (MLL-r). Study objectives are typical for a Phase 1 study, including determining safety and tolerability, identifying the maximum tolerated dose or recommended Phase 2 dose (RP2D) and schedule, and evaluating the relationship between dose, exposure and pharmacodynamic effects. In four completed dose cohorts, with a total of 16 patients dosed (including eight patients with acute leukemia with MLL-r), EPZ-5676 has been well-tolerated. There have been no dose-limiting toxicities and only one adverse event-related treatment discontinuation, which was not considered to be related to EPZ-5676. Exposure has been dose-proportional, and inhibition of the target methyl mark has been dose- and time-dependent. In four of the eight MLL-r acute leukemia patients, treatment effects consistent with the genetically defined therapeutic mechanism of action were observed, while no treatment effects were seen in the non-MLL-r patients. Treatment effects were consistent with leukemia cell differentiation and maturation, including treatment-related leukocytosis, maturation features in blood and bone marrow, and blood and bone marrow blast count reductions. Additionally, some MLL-r patients experienced resolution of leukemia-related symptoms and manifestations, including fevers, cachexia, and leukemia cutis. The study is ongoing with a fifth dose cohort (80 mg/m2/day) currently enrolling.

Based on these results, Epizyme plans to start the Phase 1 MLL-r only expansion stage with an 80 mg/m2/day administration schedule without a drug holiday and with possible continued dose escalation. This expansion stage is intended to provide an initial assessment of efficacy for EPZ-5676 in MLL-r patients.

"The observed safety and tolerability profile of EPZ-5676, along with the mechanistically consistent treatment effects in MLL-r patients, are strongly supportive of continued clinical development," said Eric Hedrick M.D., chief medical officer, Epizyme. "We believe these data warrant evaluation of an uninterrupted administration schedule of EPZ-5676 in the MLL-r only expansion stage of the ongoing Phase 1 adult trial, as well as in two additional clinical settings, both of which we plan to initiate in 2014: a Phase 1b trial in pediatric acute leukemia patients with MLL-r, and an expansion cohort in adult AML patients with the MLL-PTD genetic alteration."

About EPZ-5676
Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of acute leukemias with alterations in the MLL gene. As a result of these alterations, DOT1L is misregulated and causes inappropriate methylation, resulting in the increased expression of genes causing leukemia. Additional information about this program, including clinical trial information, may be found here: http://clinicaltrials.gov/show/NCT01684150.

Epizyme retains all U.S. rights to EPZ-5676 and has granted Celgene an exclusive license to EPZ-5676 outside of the United States. Epizyme has partnered with Abbott to develop a companion diagnostic to identify MLL-r patients. Additional information about these partnerships may be found here: www.epizyme.com/about-us/partnerships/.

Conference Call Information
Epizyme will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss initial findings from the dose escalation stage of the ongoing Phase 1 study. To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 10332364. The live webcast and accompanying slides that provide additional detail about the dose escalation stage of this study can be accessed under "Upcoming Events" in the Investor Center section of the Company's website at www.epizyme.com.

The archived webcast will be available on the Company's website beginning approximately 2 hours after the live conference call.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

[adeezl]

$18 to 45 in a month is not too shabby, even if it was on tiny fluff volume and no interest hah, that's the way of biotech and pharma

[adeezl]

Not many trading this, but it did beat estimates on the loss on both top/bottom ends.. interesting

Epizyme (NASDAQ: EPZM) reports Q2 EPS of $(0.25) to the estimated $(0.36) . Revenue came in at $14.80M to the estimated $13.40M.

CAMBRIDGE, Mass. , July 31, 2013 /PRNewswire/ -- Epizyme, Inc. , (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today provided a corporate update and reported financial results for the second quarter ended June 30, 2013 .
"The second quarter was transformative for Epizyme . We completed a successful IPO, ending the period with $149 million in cash and cash equivalents," commented Robert Gould , Ph.D., CEO of Epizyme . "We now have two programs in clinical development. The dose escalation study is ongoing for EPZ-5676, our therapeutic candidate for the treatment of acute leukemia patients with mixed lineage leukemia (MLL-r), and we plan to initiate the expansion cohort stage of this study later this year. In June, we initiated clinical development of our second program, EPZ-6438, our therapeutic candidate for the treatment of non-Hodgkin lymphoma patients with oncogenic point mutations in EZH2. As a result of the initiation of the clinical development of EPZ-6438, we earned a $6 million milestone from our partner Eisai , which was received in July. Our collaborations with Celgene , Eisai , and GSK are important elements of our business strategy, including our retained United States rights for EPZ-5676 and EPZ-6438, and as sources of potential future milestones and royalties. Today, we are in a strong position to invest in and expand Epizyme's product platform and pipeline of therapeutic programs. We look forward to additional progress across the Company this year."
Recent Business Highlights
-- Completion of Initial Public OfferingEpizyme announced on June 5, 2013 ,
that it had completed its initial public offering of common stock,
raising gross proceeds of $88.7 million .
-- Continued Progress with EPZ-5676 DevelopmentEpizyme is enrolling
patients in the dose escalation stage of its Phase 1 study of EPZ-5676
and has added four clinical sites in 2013 for a total of five active
sites at this time. The Company expects to initiate an expansion cohort
later in the year, limited to patients with MLL-r, in as many as twelve
sites in both the United States and Europe . In June, Epizyme scientists
published pre-clinical data on EPZ-5676 in the journal Blood, showing
the correlation between DOT1L inhibition and anti-proliferative effects
specific to MLL-r leukemias, including tumor growth inhibition and
durable anti-tumor effects in animal models that were sustained after
dosing had been completed.
-- Companion Diagnostic Collaboration for EPZ-5676In April, Epizyme
announced a collaboration with Abbott Molecular Inc. to develop a
molecular companion diagnostic to identify eligible patients for
EPZ-5676.
-- Initiation of Phase 1/2 Clinical Trial for EPZ-6438In June, Epizyme
announced the enrollment of its first patient in a Phase 1/2 study of
EPZ-6438 (referred to as E7438 by Eisai ). Epizyme plans to initiate the
Phase 2 portion of this study in 2014.
-- Intellectual PropertyIn April, the Company was granted the first patent
covering the composition of matter of EPZ-6438. This patent expires in
2032. In addition, in April, the US Patent and Trademark Office issued a
Notice of Allowance for a patent application titled "Diagnostic and
Therapeutic Targets for Leukemia" with claims directed to methods of
identifying DOT1L inhibitor compounds for the treatment of leukemia. The
patent to be issued from this application carries a patent term to at
least 2030.
-- Pipeline DevelopmentEpizyme continues to conduct preclinical studies to
identify additional genetically defined cancers for potential treatment
with its therapeutic candidates. In April, Epizyme scientists published
a paper in Proceedings of the National Academy of Sciences ,
demonstrating the effectiveness of a potent, selective EZH2 inhibitor in
specifically killing malignant rhabdoid tumors (MRT) that are
INI1-deficient, both in cell culture and in rodent xenograft models.
This work demonstrates for the first time the effectiveness of an EZH2
inhibitor in a solid tumor indication.


Second Quarter 2013 Financial Results & Financial Guidance
-- Cash PositionCash and cash equivalents as of June 30, 2013 , were $148.7
million , compared to $98.0 million at December 31, 2012 . The cash
increase was primarily driven by gross proceeds of $88.7 million from
Epizyme's initial public offering. Cash and cash equivalents as of June
30, 2013 did not include the $6.0 million milestone earned in the Eisai
collaboration in June, which was received in July.
-- Revenue Collaboration revenue was $14.8 million for the second quarter
of 2013 and $23.7 million for the six months ended June 30, 2013 ,
compared to $15.3 million and $21.0 million for the comparable periods
in 2012.
-- R&D Expenses Research and development expenses were $13.9 million for
the second quarter of 2013 and $27.3 million for the six months ended
June 30, 2013 , compared to $8.9 million and $18.1 million for the
comparable periods in 2012. The increase was largely driven by the
expansion of the Company's product platform and costs for the clinical
studies of EPZ-5676 and EPZ-6438.
-- G&A Expenses General and administrative expenses were $3.1 million for
the second quarter of 2013 and $6.1 million for the six months ended
June 30, 2013 , compared to $1.6 million and $3.5 million for the
comparable periods in 2012. The increase was largely driven by
incremental expenses to support public company operations as well as
increased stock-based compensation expense and other costs to support
the Company's growth.
-- Net (Loss) Income Net loss was $2.2 million for the second quarter of
2013 and $9.7 million for the six months ended June 30, 2013 , compared
to net income of $4.9 million and net loss of $0.6 million for the
comparable periods in 2012. The 2012 second quarter net income was
largely driven by the revenue recognition of a portion of the $68.0
million upfront payment received from Celgene in April 2012 .
-- End of Year Cash GuidanceEpizyme expects that its cash and cash
equivalents will be approximately $115 million as of December 31, 2013 ,
which it believes will fund the Company until at least mid-2015.
Full-year 2013 net cash used in operating activities is expected to be
approximately $65 million .


Upcoming Milestones
-- EPZ-5676In the second half of 2013, Epizyme plans to complete the dose
escalation stage of the Phase 1 study and initiate the expansion cohort,
which will be limited to patients with MLL-r and which may provide an
initial assessment of therapeutic effect.
-- EPZ-6438In 2014, Epizyme plans to initiate the Phase 2 portion of the
Phase 1/2 study of EPZ-6438, which will be limited to patients with
point mutations in EZH2 and which may provide an initial assessment of
therapeutic effect.


Conference Call Information

Epizyme will host a conference call and live audio webcast today at 4:30 p.m. EDT to discuss the quarter and provide a corporate update. To participate in the conference call, please dial 1-877-844-6886 (domestic) or 1-970-315-0315 (international) and refer to conference ID 17477005. The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com. 
The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

EPIZYME, INC.

CONSOLIDATED BALANCE SHEET DATA (UNAUDITED)

(Amounts in thousands)



June 30, December 31,

2013 2012

Cash and cash equivalents $ 148,689 $ 97,981

Total assets 162,044 103,511

Deferred revenue 56,937 69,445

Redeemable convertible preferred stock (Series A, B and - 76,156
C)

Stockholders' equity (deficit): 96,127 (51,126)

EPIZYME, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands except per share data)


Three Months Ended June 30, Six Months Ended June 30,

2013 2012 2013 2012


Collaboration revenue $ 14,839 $ 15,342 $ 23,721 $ 20,996


Operating expenses:

Research and development 13,937 8,899 27,298 18,127

General and 3,079 1,638 6,077 3,545
administrative

Total operating expenses 17,016 10,537 33,375 21,672


(Loss) income from (2,177) 4,805 (9,654) (676)
operations


Other (expense) income, (35) 51 (55) 64
net

Net (loss) income $ (2,212) $ 4,856 $ (9,709) $ (612)

Less: accretion of
redeemable convertible
preferred stock

to redemption value 107 156 264 167

Less: income allocable to - 4,354 - -
participating securities

(Loss) income allocable
to common stockholders - (2,319) 346 (9,973) (779)
basic

Undistributed income
re-allocated to common - 236 - -
stockholders

(Loss) income allocable
to common stockholders - $ (2,319) $ 582 $ (9,973) $ (779)
diluted

(Loss) earnings per share
allocable to common
stockholders:

Basic $ (0.25) $ 0.21 $ (1.82) $ (0.48)

Diluted $ (0.25) $ 0.20 $ (1.82) $ (0.48)

Weighted average shares
outstanding:

Basic 9,146 1,636 5,489 1,629

Diluted 9,146 2,913 5,489 1,629

Note:  Common shares outstanding as of the end of the second quarter of 2013 were 28.4 million following the sale of 5.9 million shares of common stock, including all additional shares sold to cover over-allotments, in the Company's initial public offering and the resulting automatic conversion of the Company's redeemable convertible preferred stock into 20.6 million shares of common stock, compared to 1.6 million common shares as of the end of the second quarter of 2012. The Company's weighted average shares outstanding for the second quarter of 2013 were 9.1 million shares.

[biocqr]

$1B mc with zero clinical data... I would be careful.

[adeezl]

Pump from cramer on squawk box gave us a nice pop for more volume in 30 mins than most of our average daily. I think this easily goes to $42. talk about an IPO under the radar

[Ganthid]

Anyone have any advice on how to properly evaluate a company like this? I'm relatively new to investing and think genetic cancer drugs will be huge. I've looked over some numbers but the major thing I took away is that major players are putting money into this (Glaxo Smith and Kline).

[adeezl]

wow explosive day here on low volume.. something is brewing here folks

[adeezl]

I let it go on the open got 27.90/92 very happy with this trade! Thanks Epizyme!

[adeezl]

wow $24 to $27 intraday hah nice! I may let mine go tomorrow morning from 24.50

[adeezl]

Very nice day here with some volume... looks good to me anyone notice the phase trial going up last thursday's news?

http://www.epizyme.com/Epizyme%20Enrolls%20First%20Patient%20in%20Phase%2012%20Clinical%20Trial%20of%20EPZ-6438,%20an%20Inhibitor%20of%20EZH2.pdf

http://www.marketwatch.com/story/epizyme-enrolls-first-patient-in-phase-12-clinical-trial-of-epz-6438-an-inhibitor-of-ezh2-2013-06-13

Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
Company Earns $6 Million Milestone Payment from Eisai for Trial Initiation

CAMBRIDGE, Mass., June 13, 2013 /PRNewswire via COMTEX/ -- Epizyme, Inc., EPZM +10.66% a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled in a Phase 1/2 clinical trial of EPZ-6438 (E7438). The trial is designed to assess the safety, tolerability and pharmacokinetics of EPZ-6438 (E7438), an orally available, small molecule inhibitor for non-Hodgkin lymphoma patients who have a cancer-causing (oncogenic) point mutation in EZH2.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In April 2011, the two companies announced a worldwide partnership to discover, develop and commercialize therapeutics targeting EZH2, with Epizyme retaining an opt-in right to co-develop, co-commercialize and share profits with Eisai on licensed products in the United States. As a result of the first patient enrollment in this trial, Epizyme earned a $6 million milestone payment from Eisai.

About EZH2 Cancers

EZH2 is a histone methyltransferase (HMT) that can become oncogenic and cause non-Hodgkin lymphoma and solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are mainly associated with oncogenic EZH2 mutations. Currently, there are no therapies approved specifically for the treatment of non-Hodgkin lymphoma associated with an EZH2 point mutation.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing).

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

[adeezl]

Check these Form-4's - $6mil each by holders bought with firms buying a ton, very interesting folks

SOURCE: Form 4

ISSUER: EPIZYME INC
SYMBOL: EPZM

FILER: NEW ENTERPRISE ASSOCIATES 13 LP
TITLE: Beneficial Owner

DATE TRANSACTION SHARES PRICE VALUE
6/5/13 - Purchase - 400,000 - $15.00 - $6,000,000

OWNERSHIP: 6,033,240 (Direct)

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction

SOURCE: Form 4

ISSUER: EPIZYME INC
SYMBOL: EPZM

FILER: SANDELL SCOTT D
TITLE: Beneficial Owner

DATE TRANSACTION SHARES PRICE VALUE
6/5/13 - Purchase - 400,000 - $15.00 - $6,000,000

OWNERSHIP: 6,033,240 (Indirect)

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.

SOURCE: Form 4

ISSUER: EPIZYME INC
SYMBOL: EPZM

FILER: VISWANATHAN RAVI
TITLE: Beneficial Owner

DATE TRANSACTION SHARES PRICE VALUE
6/5/13 - Purchase - 400,000 - $15.00 - $6,000,000

OWNERSHIP: 6,033,240 (Indirect)

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.

SOURCE: Form 4

ISSUER: EPIZYME INC
SYMBOL: EPZM

FILER: WELLER HARRY R
TITLE: Beneficial Owner

DATE TRANSACTION SHARES PRICE VALUE
6/5/13 - Purchase - 400,000 - $15.00 - $6,000,000

OWNERSHIP: 6,033,240 (Indirect)

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.

SOURCE: Form 4

ISSUER: EPIZYME INC
SYMBOL: EPZM

FILER: BAY CITY CAPITAL LLC
TITLE: Beneficial Owner

DATE TRANSACTION SHARES PRICE VALUE
6/5/13 - Purchase - 166,666 - $15.00 - $2,499,990

OWNERSHIP: 3,658,729 (Indirect)

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.

SOURCE: Form 4

ISSUER: EPIZYME INC
SYMBOL: EPZM

FILER: ASTELLAS VENTURE FUND I L.P
TITLE: Beneficial Owner

DATE TRANSACTION SHARES PRICE VALUE
6/5/13 - Purchase - 15,333 - $15.00 - $229,995

OWNERSHIP: 650,253 (Direct)

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.

[adeezl]

wow lots of 400k buys here in form-4's should be interesting monday.. gaining traction here I like the fire. Cheers